Therefore, angiogenesis is currently considered as a novel therapeutic target for DMD [61,62] and administration of angiogenic factors, including VEGF and FGF, has been tested as potential treatment to enhance vascularization in ischemic diseases [63]. This evidence concerns the gene VEGFA and Duchenne muscular dystrophy.